Tocilizumab.
Roche is co-developing tocilizumab (Actemra, RoActemra), a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody, with Chugai Pharmaceutical. Tocilizumab is marketed in Japan for Castleman disease and several types of arthritis. The product is approved in the European Union for treatment of moderate-to-severe rheumatoid arthritis, and is currently undergoing review by the US Food and Drug Administration for this condition. Tocilizumab has also been studied for potential use in the treatment of other IL-6 related disorders including Crohn disease.
Venkiteshwaran
Adith
A
Rensselaer Polytechnic Institute, Troy, NY, USA. sohini.mazumdar@tufts.edu
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005871:Castleman Disease / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003424:Crohn Disease / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005062:European Union; D006801:Humans; D007564:Japan; D051379:Mice; D019947:Receptors, Interleukin-6 / Q000276:immunology*; D016896:Treatment Outcome; D014481:United States
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D019947:Receptors, Interleukin-6; C502936:tocilizumab